Using immune cells from soft tissue sarcoma to create personalized cancer treatments
Official title: Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10889139 · Data updated 2026-11-12
This study is testing a new cancer treatment that uses your own immune cells to help fight metastatic soft tissue sarcoma, and it's designed for patients like you who want a personalized approach to their care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 1, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $245,296 |
| NIH project number | 5K08CA252642-05 |
| Project ID | NIH-10889139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic soft tissue sarcoma who are seeking innovative treatment options.
✕Less likely to help
Patients with early-stage soft tissue sarcoma or those who do not have sufficient tumor tissue for immune cell extraction may not benefit from this research.
What this research studies
This research focuses on developing a new type of cancer treatment called autologous cellular immunotherapy, which uses immune cells taken from patients' own tumors. The principal investigator, Dr. Mullinax, aims to expand tumor-infiltrating lymphocytes (TIL) from soft tissue sarcoma to create a personalized therapy that targets the cancer more effectively. The study will assess the safety and feasibility of this treatment in patients with metastatic soft tissue sarcoma, leveraging advanced bioinformatics and clinical trial methodologies. Patients participating in this trial will contribute to the understanding of how their immune cells can be used to fight their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients with soft tissue sarcoma.
How similar studies have gone: Previous research has shown promising results with similar approaches in other types of cancers, indicating potential for success in this novel application.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Mullinax, John — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Mullinax, John
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Soft Tissue Sarcoma: targeted therapies and biomarkers to help patients
A big research effort at a major cancer center aims to develop targeted treatments and biomarkers to improve outcomes for people with soft tissue sarcoma.
-
Ultra-steerable ultrasound therapy for soft tissue sarcoma
A new ultrasound device is being developed to non-invasively shrink or remove soft tissue sarcomas while protecting nearby nerves, blood vessels, and bones.
-
Robotic ultrasound system to non-invasively remove soft tissue sarcoma
A robotic ultrasound approach aims to precisely destroy soft tissue sarcoma tumors without open surgery for people with large or hard-to-reach tumors.
-
Boosting NK-cell therapy for soft tissue sarcoma using a dog model
This project combines an antibody that soaks up a tumor-made immune blocker with natural killer (NK) cell therapy to help dogs and, eventually, people with soft tissue sarcoma fight their tumors.
-
Targeted treatments for soft tissue sarcoma
This project is testing targeted drugs and immunotherapies for people with soft tissue sarcoma, including adults and children.
-
Enhancing cancer treatment using natural killer cells in dogs with soft tissue sarcoma
This study is looking at a new way to help treat soft tissue sarcoma in dogs by using special immune cells called natural killer cells, along with a targeted antibody, to make the treatment more effective and hopefully improve outcomes for our furry friends.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.